HBM HOLDINGS-B (02142) Rises Over 4% Again on Deepened Collaboration with AstraZeneca for Next-Gen Oncology Therapies

Stock News11-27

HBM HOLDINGS-B (02142) surged over 4% again, trading at HK$14.22 by press time with a turnover of HK$27.85 million, marking a 4.25% gain. The company announced an update and expansion of its global strategic collaboration with AstraZeneca PLC (AZN), initially established in March 2025. Under the enhanced partnership, both parties will leverage their respective expertise to co-develop next-generation biologic therapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs).

Per the agreement, AstraZeneca will nominate R&D projects annually over the next four years, retaining option rights for licensing these programs—a move underscoring the deepening alliance. HBM HOLDINGS-B stands to receive option fees, exercise payments, development/commercial milestone payments, and tiered royalties on future net sales of licensed products. Financial terms align with the framework agreed upon in March 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133618506?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 10:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133618506","market":"fut","top_or_hot":-1,"title":"HBM HOLDINGS-B (02142) Rises Over 4% Again on Deepened Collaboration with AstraZeneca for Next-Gen Oncology Therapies","media":"Stock News","content":"<p>HBM HOLDINGS-B (02142) surged over 4% again, trading at HK$14.22 by press time with a turnover of HK$27.85 million, marking a 4.25% gain. The company announced an update and expansion of its global strategic collaboration with AstraZeneca PLC (AZN), initially established in March 2025. Under the enhanced partnership, both parties will leverage their respective expertise to co-develop next-generation biologic therapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs).</p>\n<p>Per the agreement, AstraZeneca will nominate R&D projects annually over the next four years, retaining option rights for licensing these programs—a move underscoring the deepening alliance. HBM HOLDINGS-B stands to receive option fees, exercise payments, development/commercial milestone payments, and tiered royalties on future net sales of licensed products. Financial terms align with the framework agreed upon in March 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM HOLDINGS-B (02142) Rises Over 4% Again on Deepened Collaboration with AstraZeneca for Next-Gen Oncology Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM HOLDINGS-B (02142) Rises Over 4% Again on Deepened Collaboration with AstraZeneca for Next-Gen Oncology Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-27 10:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HBM HOLDINGS-B (02142) surged over 4% again, trading at HK$14.22 by press time with a turnover of HK$27.85 million, marking a 4.25% gain. The company announced an update and expansion of its global strategic collaboration with AstraZeneca PLC (AZN), initially established in March 2025. Under the enhanced partnership, both parties will leverage their respective expertise to co-develop next-generation biologic therapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs).</p>\n<p>Per the agreement, AstraZeneca will nominate R&D projects annually over the next four years, retaining option rights for licensing these programs—a move underscoring the deepening alliance. HBM HOLDINGS-B stands to receive option fees, exercise payments, development/commercial milestone payments, and tiered royalties on future net sales of licensed products. Financial terms align with the framework agreed upon in March 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1133618506","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133618506","pubTimestamp":1764210259,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HBM HOLDINGS-B (02142) surged over 4% again, trading at HK$14.22 by press time with a turnover of HK$27.85 million, marking a 4.25% gain. The company announced an update and expansion of its global...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK1161":"生物科技","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK1574":"生物医药B类股","02142":"和铂医药-B","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4568":"美国抗疫概念","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK1583":"高瓴概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4007":"制药","AZN":"阿斯利康","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"HBM HOLDINGS-B(02142)与阿斯利康深化下一代肿瘤疗法合作再次涨超4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"02142":1},"content_text":"HBM HOLDINGS-B (02142) surged over 4% again, trading at HK$14.22 by press time with a turnover of HK$27.85 million, marking a 4.25% gain. The company announced an update and expansion of its global strategic collaboration with AstraZeneca PLC (AZN), initially established in March 2025. Under the enhanced partnership, both parties will leverage their respective expertise to co-develop next-generation biologic therapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs).\nPer the agreement, AstraZeneca will nominate R&D projects annually over the next four years, retaining option rights for licensing these programs—a move underscoring the deepening alliance. HBM HOLDINGS-B stands to receive option fees, exercise payments, development/commercial milestone payments, and tiered royalties on future net sales of licensed products. Financial terms align with the framework agreed upon in March 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133618506","isCrawlerRequest":true}